The Relationship between Exhaled Nitric Oxide Measured with an Off-line Method and Airway Reversible Obstruction in Japanese Adults with Asthma  by Tsuburai, Takahiro et al.
Allergology International Vol 56, No1, 2007 www.jsaweb.jp 37
Awarded Article, Annual Meeting of JSA
The Relationship between Exhaled
Nitric Oxide Measured with an Off-line
Method and Airway Reversible
Obstruction in Japanese Adults with
Asthma
Takahiro Tsuburai1, Naomi Tsurikisawa1, Masami Taniguchi1, Sonoko Morita1, Emiko Ono1,
Chiyako Oshikata1, Mamoru Ohtomo1, Yuji Maeda1, Kunihiko Ikehara2 and Kazuo Akiyama1
ABSTRACT
Background: Exhaled nitric oxide (eNO) is a useful marker of eosinophilic airway inflammation in asthma pa-
tients. There is no study to show the relationship between the eNO measured by using an off-line method and
the degree of reversibility of airflow limitation in Japanese asthma patients. We sought to investigate the rela-
tionship between the eNO level measured by using an off-line method and the degree of reversibility of bron-
chial constriction in Japanese asthma patients.
Methods: The study population comprised 97 asthma patients in our outpatient clinic with some patients in
both groups who received inhaled corticosteroid treatment. We measured eNO levels, forced expiratory volume
in one second (FEV1) before and after treatment, reversible airway obstruction (∆FEV1) after inhalation of bron-
chodilator, and other parameters.
Results: eNO was significantly correlated with peripheral blood eosinophil counts in asthma patients (in
steroid-naïve asthma patients, r = 0.544, p < 0.0001; in asthma patients treated with inhaled corticosteroid, r =
0.463, p = 0.026), and subjects with severe eosinophilia in sputum showed high levels of eNO (mild eosino-
philia versus severe, p = 0.0152). Among patients with obstructive impairment, eNO levels were correlated with
∆FEV1 regardless of whether patients received (r = 0.527, p = 0.0435) or did not receive (r = 0.64, p = 0.0056)
inhaled corticosteroid. In subjects with normal pulmonary function, there was no significant relationship be-
tween eNO and ∆FEV1 with or without inhaled corticosteroid.
Conclusions: In patients with obstructive impairment, eNO reflects the degree of reversible airflow limitation.
In subjects with normal pulmonary function, eNO may facilitate the diagnosis and management of asthma,
rather than indicate reversible bronchial obstruction. eNO measurement by off-line methods is applicable as a
potential tool for the diagnosis of asthma and management of asthma patients.
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INTRODUCTION
Bronchial asthma is caused by eosinophilic bronchial
inflammation. Inhaled corticosteroid (ICS), the main-
stay of asthma treatment, is effective because it pre-
vents this inflammatory process. Therefore, quantifi-
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cation of airway inflammation may provide additional
information for both diagnosis and management of
bronchial asthma. However the current asthma man-
agement guideline (GINA: Global Initiative for
Asthma) relies on monitoring respiratory function
and symptoms.1 Three studies have demonstrated
that adding alternative monitoring markers such as
airway hyperresponsiveness, eosinophilia in induced
sputum, and exhaled nitric oxide (eNO) to current
guidelines on dose adjustment of ICS leads to im-
proved outcomes.2-4
According to recent studies, eNO is a useful
marker of airway eosinophilic inflammation in
asthma.5,6 The increased levels of eNO are due to ac-
tivation of NO synthase in airway epithelial and in-
flammatory cells.7-9 Measurement of eNO is simple,
noninvasive, and repeatable. eNO levels are higher in
asthma patients than in healthy subjects,10 and eNO
levels fall after treatment with corticosterids.11 In
steroid-naïve asthma patients, eNO levels correlate
with peripheral eosinophils in blood, eosinophils in
induced sputum, airway reversible limitation, or bron-
chial hyperresponsiveness,12-16 so that eNO is useful
in the diagnosis of asthma patients.17,18 In asthma pa-
tients treated with ICS, eNO levels correlate with pe-
ripheral eosinophils in the blood, but are not corre-
lated with eosinophils in induced sputum or bronchial
hyperresponsiveness.19 However, eNO levels corre-
late with the following markers of disease control:
asthma symptoms within the prior 2 weeks, disease
score, and reversibility of airflow obstruction of bron-
chial asthma.20 Furthermore, eNO is useful in the
clinical management4 of asthma patients treated with
ICS. These findings suggest that eNO is not only use-
ful in steroid-naïve asthma patients, but also useful as
a marker of disease control in asthma patients treated
with ICS.
Despite the utility of the eNO measurement, NO
analyzers are too expensive for widespread use by
general practitioners. In comparison, the off-line (bag
collection) method of eNO measurement may be
more useful.5,6,21 In contrast to on-line techniques,
off-line collection methods offer the following bene-
fits: (1) the potential for expirate collection at sites re-
mote from the analyzer; (2) more efficient use of the
analyzer because exhaled gas can be collected and
stored for a while from several patients or several
places and analyzed in a batch, possibly with notable
cost savings. Recent studies have demonstrated that
eNO measurement in the off-line method has sensi-
tivity and specificity in which is comparable to the on-
line method,22-25 especially in asthmatic children.
However in Japan, there have been few studies on the
use of eNO in asthma patients using the off-line
method. Therefore, we sought to investigate the rela-
tionship between eNO levels measured by using an
off-line method and the level of bronchial reversibility
in Japanese asthma patients.
METHODS
SUBJECTS
The study population was recruited from adult outpa-
tients with bronchial asthma (n = 97) at the Clinic of
Allergy and Respiratory Medicine in the Sagamihara
National Hospital from June 2003 until February
2005. All patients gave full informed consent to par-
ticipate in the study. Each subject underwent a stan-
dard clinical assessment, which included a history
and physical examination, laboratory tests (including
eosinophil counts in peripheral blood), and chest ra-
diograph. The diagnosis of asthma was based on ap-
plication of the GINA guidelines by an experienced
respiratory physician blinded to the result of eNO
measurement.1 The clinical severity of asthma (Step)
was classified according to these guidelines.1 Atopy
was indicated by a positive skin test to mites or
housedust, or serum IgE >250 IUml. Exclusion crite-
ria included current smokers or ex-smokers of
greater than 20 packs per year, rescue use of oral cor-
ticosteroids within the preceding four weeks, preg-
nancy, and any other respiratory disease. The study
protocol (no. 14, 2003) was approved by the ethical
committee at our hospital .
eNO MEASUREMENT
Exhaled air was collected according to the recom-
mendation of ATSERS by using bag collection kits
(Sievers Instrument, Boulder, Colo).5,6 Briefly, sub-
jects inhaled deep breaths of room air through the
NO scavenging filter and exhaled through a mouth-
piece with a flow rate of 70 ml per second against an
expiratory resistance of 10 cm H2O and, 5 seconds
later, exhaled air was collected into the 1.5 liter Mylar
bag provided in the kit. The NO concentration in the
collected exhaled air was measured within 12 hours.
The air was drawn out of the balloons at 200 ml per
minute into an NO chemiluminescence analyzer
(NOA model 280A, Sievers Instrument) with a re-
sponse time of 200 milliseconds. The normal range of
eNO was determined in 14 healthy non-atopic, non-
smoking volunteers. Their mean value was 21.1 ppb;
the 95%CI was 15.0―27.1 ppb. Regarding this range,
we considered basal concentrations≧27.2 ppb as the
cutoff values.
SPIROMETRY
After the eNO samples were collected, all subjects
underwent spirometry with an electric spirometer
(Minato Autospiro AS-302, Japan). The forced expira-
tory volume in 1 second (FEV1) was expressed as
percentage of forced vital capacity (FVC). The revers-
ible change of FEV1 was expressed before and 30
minutes after inhaling 200 μg salbutamol. The degree
of reversible airflow limitation was defined as ∆FEV1,
which is equal to (FEV1post-bronchodilator − FEV1baseline)
× 100FEV1baseline (%).
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Fig. 1 Corelation between eNO and FEV1/FVC (%) (A) or FEV1 (L) (B). Triangles, 
asthma patients treated without inhaled corticosteroid (ICS); Circles, asthma patients 
treated with ICS.; Open symbols, FEV1/FVC≧ 70%; Solid symbols, FEV1/FVC＜ 70%; 
NS, not statisticaly significant. The vertical line represents FEV1/FVC＝70%, and the hori
zontal line represents eNO＝27.2 ppb.
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Table 1 Patient demographics. Data are presented as 
mean ± standard eror of the mean.
Bronchial asthma
Without ICSWith ICS
23/3911/24Sex (Men/Women)
40.9 ± 1.9348.6 ± 2.68Age (year)
42/1926/9 Atopy/non-atopy
5.68 ± 1.0712.5 ± 2.41Duration of disease (year)
23 6Step 1
13 92
19143
 6 64
75.5 ± 1.3368.1 ± 2.51FEV1/FVC (%)
93.0 ± 2.1881.6 ± 3.87%FEV1 (%predict)
6.46 ± 0.637.02 ± 1.00Eosinophil in blood (%)
Eosinophil in sputum
(10/8/21)(1/0/6)(mild/moderate/severe)
61.7 ± 5.7046.9 ± 4.37eNO (parts per bilion; ppb)
7.98 ± 0.1213.5 ± 0.13DFEV1 (%)
6.5%9.8%median
EOSINOPHILIA IN SPUTUM
Sputum was collected and analyzed using the Han-
sel’s modified method (Eosinostein©, Torii Pharma-
ceutical Co., Tokyo, Japan).26 Briefly, each sputum
sample was smeared on a glass slide and stained for
45 seconds. All samples were analyzed by an experi-
enced investigator (A.S.) who was blinded to the
clinical data of the patients. The level of eosinophilia
was scored as: mild, no or few eosinophils through-
out the entire smear; moderate, several eosinophils in
each high-power (×400) microscopic field; severe, nu-
merous eosinophils in each high-power (×400) micro-
scopic field.
STATISTICAL ANALYSIS
Correlations were determined using the Spearman
rank correlation. A paired-sample t test was used to
analyze eNO measurements and FEV1, ∆FEV1 or pe-
ripheral eosinophil percentage in blood; p < 0.05 was
considered significant. Analysis of variance was used
to compare eNO measures between groups accord-
ing to the level of eosinophilia in the sputum.
RESULTS
We classified the 97 asthma patients into two groups
in regard to their therapeutic backgrounds: (A) 35
asthma patients treated with ICS (ICS(+)) and (B) 62
stable asthma patients treated without ICS (ICS(−))
(Table 1).
There was no relationship between eNO levels and
either FEV1 (L) or FEV1FVC (%) among the patients
in either groups (Fig. 1A, B). The peripheral eosino-
phil percentage in blood was correlated with the eNO
levels in each group (steroid-naïve asthma patients,
r = 0.544, p < 0.0001, Fig. 2A; asthma patients with
ICS, r = 0.463, p = 0.026, Fig. 2B).
Sputum was collected from 7 of the 35 subjects
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Fig. 2 Corelation between eNO and peripheral eosinophil percentage in blood. (A) 
asthma patients treated without ICS (triangles). (B) asthma patients treated with ICS 
(circles). Open, FEV1/FVC＞＿ 70%; Solid, FEV1/FVC＜70%. The vertical line represents 
peripheral eosinophilia in blood＝5%, and the horizontal line represents eNO＝27.2 ppb.
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Fig. 3 The amounts of eNO at each level of eosinophilia in 
the sputum. Triangles, asthma patients treated without ICS; 
Circles, asthma patients treated with ICS. The horizontal 
line represents eNO＝27.2 ppb.
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(20%) in the ICS (+) group and from 39 of the 62 sub-
jects (62.9%) in the ICS (−) group. The eNO levels of
the subjects with severe eosinophilia in the sputum
were significantly (p = 0.0152) higher than those of
patients with no or mild eosinophilia in the sputum
(Fig. 3).
To investigate whether the level of airway eosino-
philic inflammation influences the degree of obstruc-
tive impairment, we classified each of the ICS (+) and
ICS (−) groups into two subgroups according to the
results of the respiratory function tests: (1) asthma
patients with airflow limitation in the respiratory func-
tion test (FEV1FVC < 70%) and (2) asthma patients
with normal function (FEV1FVC 70%).
Among the patients with obstructive impairment,
eNO levels were correlated with ∆FEV1 in the ICS (−)
subjects (group A, r = 0.64, p = 0.0056, Fig. 4A). In ad-
dition, eNO levels were also correlated with ∆FEV1 in
the ICS (+) subjects (group B, r = 0.527, p = 0.0435,
Fig. 4B). For subjects with normal pulmonary func-
tion, there was no significant relationship between
eNO levels and ∆FEV1 in either the ICS (−) (Fig. 5A)
or the ICS (+) (Fig. 5B) subjects. The eNO levels of
24 out of 36 ICS (−) subjects or the eNO levels of 10
out of 17 ICS (+) subjects were higher than 27.2 ppb
despite the low levels of ∆FEV1.
DISCUSSION
In asthma patients with airflow limitation who were
treated either with or without ICS, eNO levels were
significantly associated with ∆FEV1. However, in
asthma patients with normal respiratory function who
were treated either with or without ICS, there was no
significant relationship between eNO and ∆FEV1. In
mild asthma conditions, there is eosinophilic inflam-
mation of bronchial mucosa, even if the patient’s res-
piratory function is normal. This might explain why
there was no significant relationship between eNO
and ∆FEV1 in asthma patients with currently normal
respiratory function. Furthermore this suggests that
the biomarker reflecting airway inflammation can be
useful for diagnosis and disease control in asthma pa-
tients.
eNO levels and the percentage of eosinophils in
the peripheral blood are significantly correlated, and
eNO Measurement and Airway Reversibility
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Fig. 4 Corelation between eNO and ∆FEV1 (%) in asthma patients with obstructive 
impairment. (A) asthma patients treated without ICS (solid triangles). (B) asthma patients 
treated with ICS (solid circles). The vertical line represents ∆FEV1＝12%, and the horizon
tal line represents eNO＝27.2 ppb.
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Fig. 5 Corelation between eNO and ∆FEV1 (%) in asthma patients with normal respira
tory function. (A) asthma patients treated without ICS (open triangles). (B) asthma patients 
treated with ICS (open circles). The vertical line represents ∆FEV1＝12%, and the horizon
tal line represents eNO＝27.2 ppb.
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subjects with severe eosinophilia in sputum show
high levels of eNO. The relationship between eNO
levels and the percentage of eosinophils in peripheral
blood in our study is compatible to a recent study.12
The correlation between eNO levels and eosinophilia
in sputum is not clearly demonstrated in our study. In
our study, samples were collected from only 46 sub-
jects (7 of 35 subjects in the ICS (+) group or from 39
of 62 subjects in the ICS (−) group), because the sam-
ples were collected from spontaneously expectorated
sputum. The number of samples was too small to di-
vide the subjects into two groups for analysis. Recent
studies have shown that eNO levels correlate with
eosinophils in induced sputum in steroid-naïve pa-
tients, but not in asthma patients treated with
ICS.12,19 Our sputum results are mainly reflected in
the steroid-naïve subjects. These findings suggest
that eNO is a useful marker of eosinophilic airway in-
flammation in patients without ICS treatment, and
eNO partially reflects eosinophilic inflammation in
those with ICS treatment.
In asthma patients with airflow limitation who were
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treated either with or without ICS, eNO levels were
significantly associated with ∆FEV1. The data from
the asthma patients with airflow limitation and those
treated with ICS suggest that eNO levels may be use-
ful for detecting deterioration of asthma control, and
the findings from the asthma patients treated without
ICS indicate that eNO may be useful for diagnosing
asthma in the patients with reversible airway obstruc-
tion. In a recent study, Sippel et al. noted that eNO
levels correlate with reversibility of airflow obstruc-
tion in asthma patients treated with or without ICS
and that elevated eNO levels may reflect the pres-
ence of inflammation treatable with anti-inflammatory
drugs.20 Our current findings support their conclu-
sion.
In asthma patients with normal respiratory function
who were treated either with or without ICS, there
was no significant relationship between eNO and
∆FEV1. In this group, eNO levels in some subjects
were high despite low levels of ∆FEV1. In such sub-
jects (who have ‘cough variant’ asthma), the diagno-
sis of asthma is often difficult because lung function
tests such as spirometry or the reversibility of airway
obstruction have a low sensitivity for diagnosing
asthma in those patients, so that the markers of air-
way inflammation can be useful in such subjects. The
tests for bronchial hyperresponsiveness and eosino-
phil count in induced sputum have high sensitivity,
but they are relatively invasive.27 eNO measurement
offers advantages over the previous tests because it is
quick, easy to perform, and absolutely noninvasive.
Previous studies have shown that eNO is useful in di-
agnosing mild asthma,17,18 and our results are com-
patible with the findings in these studies. In addition,
our findings for asthma patients treated without ICS
show that eNO measurement may be more useful for
diagnosing asthma than the test of reversible airway
obstruction. Furthermore, our data from subjects
treated with ICS show that the eNO may be useful in
determining which patients who would benefit from
anti-inflammatory therapy among asthma patients
with normal pulmonary function. In fact, recent stud-
ies4,20 have shown that eNO levels are correlated with
various measures of disease control in asthma, and
that eNO measurement is useful for assessing the
treatment effect in asthma patients. Our data are com-
patible with these studies.
In summary, the current study shows that the eNO
levels measured using an off-line method correlate
with the degree of reversible obstructive impairment
in Japanese adult asthma patients with airflow limita-
tion. Our findings suggest that monitoring eNO will
facilitate the diagnosis and management of bronchial
asthma. We need further long-term studies and stud-
ies to find the association between eNO levels and
bronchial hyperresponsiveness to determine the clini-
cal value of monitoring eNO levels.
ACKNOWLEDGEMENTS
Pulmonary function tests were performed by Mr.
Masayuki Kimura, Ms. Yumiko Takeuchi, and Ms.
Masayo Morie. Eosinophil sputum counts were per-
formed by Ms. Akemi Saito. The authors are in-
debted to Ms. Mayumi Sato and Ms. Misuzu Matsu-
moto for secretarial assistance. This study was sup-
ported by a grant from the Japanese Society of Aller-
gology. This study received an article award at the
2004 meeting of the Japanese Society of Allergology.
REFERENCES
1. National Institutes of Health, National Heart, Lung, and
Blood Institute. Global Strategy for Asthma Management
and Prevention: Global Initiative For Asthma 2002. NIH
Publication No 02-3659. Bethesda: National Institute of
Health, 2002.
2. Sont JK, Willems LN, Bel EH, van Krieken JH, Vanden-
broucke JP, Sterk PJ. Clinical control and histopathologic
outcome of asthma when using airway hyperresponsive-
ness as an additional guide to long-term treatment. The
AMPUL Study Group. Am. J. Respir. Crit. Care Med. 1999;
159:1043-1051.
3. Green RH, Brightling CE, McKenna S et al. Asthma exac-
erbations and sputum eosinophil counts: a randomised
controlled trial. Lancet 2002;360:1715-1721.
4. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor
DR. Use of exhaled nitric oxide measurements to guide
treatment in chronic asthma. N. Engl. J. Med. 2005;352:
2163-2173.
5. American Thoracic Society Board of Directors. Recom-
mendations for standardized procedures for the on-line
and off-line measurement of exhaled lower respiratory ni-
tric oxide and nasal nitric oxide in adults and children-
1999. This official statement of the American Thoracic So-
ciety was adopted by the ATS Board of Directors, July
1999. Am. J. Respir. Crit. Care Med. 1999;160:2104-2117.
6. American Thoracic Society Board of Directors. ATSERS
Recommendations for Standardized Procedures for the
Online and Offline Measurement of Exhaled Lower Respi-
ratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am. J.
Respir. Crit. Care Med. 2005;171:912-930.
7. van den Toorn LM, Overbeek SE, de Jongste JC, Leman
K, Hoogsteden HC, Prins JB. Airway inflammation is pre-
sent during clinical remission of atopic asthma. Am. J.
Respir. Crit. Care Med. 2001;164:2107-2113.
8. Hamid Q, Springall DR, Riveros-Moreno V et al. Induction
of nitric oxide synthase in asthma. Lancet 1993;342:1510-
1513.
9. Saleh D, Ernst P, Lim S, Barnes PJ, Giaid A. Increased
formation of the potent oxidant peroxynitrite in the air-
ways of asthmatic patients is associated with induction of
nitric oxide synthase: effect of inhaled glucocorticoid.
Faseb. J. 1998;12:929-937.
10. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R,
Shinebourne EA, Barnes PJ. Increased nitric oxide in ex-
haled air of asthmatic patients. Lancet 1994;343:133-135.
11. Yates DH, Kharitonov SA, Robbins RA, Thomas PS, Bar-
nes PJ. Effect of a nitric oxide synthase inhibitor and a
glucocorticosteroid on exhaled nitric oxide. Am. J. Respir.
Crit. Care Med. 1995;152:892-896.
12. Reid DW, Johns DP, Feltis B, Ward C, Walters EH. Ex-
haled nitric oxide continues to reflect airway hyperre-
eNO Measurement and Airway Reversibility
Allergology International Vol 56, No1, 2007 www.jsaweb.jp 43
sponsiveness and disease activity in inhaled cortico-
steroid-treated adult asthmatic patients. Respirology 2003;
8:479-486.
13. Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of dif-
fering doses of inhaled budesonide on markers of airway
inflammation in patients with mild asthma. Thorax 1999;
54:108-114.
14. Dupont LJ, Rochette F, Demedts MG, Verleden GM. Ex-
haled nitric oxide correlates with airway hyperresponsive-
ness in steroid-naive patients with mild asthma. Am. J.
Respir. Crit. Care Med. 1998;157:894-898.
15. Berlyne GS, Parameswaran K, Kamada D, Efthimiadis A,
Hargreave FE. A comparison of exhaled nitric oxide and
induced sputum as markers of airway inflammation. J. Al-
lergy Clin. Immunol. 2000;106:638-644.
16. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes
PJ. Correlation between exhaled nitric oxide, sputum
eosinophils, and methacholine responsiveness in patients
with mild asthma. Thorax 1998;53:91-95.
17. Smith AD, Cowan JO, Filsell S et al. Diagnosing asthma:
comparisons between exhaled nitric oxide measurements
and conventional tests. Am. J. Respir. Crit. Care Med.
2004;169:473-478.
18. Chatkin JM, Ansarin K, Silkoff PE et al. Exhaled nitric ox-
ide as a noninvasive assessment of chronic cough. Am. J.
Respir. Crit. Care Med. 1999;159:1810-1813.
19. Tsujino I, Nishimura M, Kamachi A et al. Exhaled nitric
oxide―is it really a good marker of airway inflammation
in bronchial asthma? Respiration 2000;67:645-651.
20. Sippel JM, Holden WE, Tilles SA et al. Exhaled nitric ox-
ide levels correlate with measures of disease control in
asthma. J. Allergy Clin. Immunol. 2000;106:645-650.
21. Silkoff PE, Stevens A, Pak J, Bucher-Bartelson B, Martin
RJ. A method for the standardized offline collection of ex-
haled nitric oxide. Chest 1999;116:754-759.
22. Deykin A, Massaro AF, Drazen JM, Israel E. Exhaled ni-
tric oxide as a diagnostic test for asthma: online versus
offline techniques and effect of flow rate. Am. J. Respir.
Crit. Care Med. 2002;165:1597-1601.
23. Barreto M, Villa MP, Martella S et al. Off-line exhaled ni-
tric oxide measurements in children. Pediatr. Pulmonol.
2001;32:159-167.
24. Jobsis Q, Schellekens SL, Kroesbergen A, Hop WC, de
Jongste JC. Off-line sampling of exhaled air for nitric ox-
ide measurement in children: methodological aspects.
Eur. Respir. J. 2001;17:898-903.
25. Jobsis Q, Raatgeep HC, Hop WC, de Jongste JC. Con-
trolled low flow off line sampling of exhaled nitric oxide in
children. Thorax 2001;56:285-289.
26. Hansel FK. On the Hansel stain. Ann. Allergy 1977;39:
142.
27. Gibson PG, Henry RL, Thomas P. Noninvasive assess-
ment of airway inflammation in children: induced sputum,
exhaled nitric oxide, and breath condensate. Eur. Respir.
J. 2000;16:1008-1015.
